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Background. The aim of this study was to investigate the antitumor effectiveness of electrochemotherapy with cis-
platin combined with suboptimal radiotherapy doses. Tumor radiosensitization was evaluated on large invasive ductal 
carcinoma tumors in Balb/C mice. 
Materials and methods. Tumors of an average volume of 630 mm3 were treated with cisplatin, electric pulses, 
radiotherapy, electrochemotherapy, alone as well as in appropriate combinations. Tumors were irradiated with 
Cobalt-60 γ-rays at doses 3 Gy and 5 Gy in combination with electrochemotherapy using cisplatin. Controls included 
each of the treatments alone as well as the combination of the radiotherapy with electric pulses alone or with cisplatin 
alone. Antitumor effectiveness was evaluated by tumor growth delay, tumor-doubling time, inhibition ratio and the 
objective response rates. 
Results. As anticipated, electrochemotherapy was more effective than the treatment with cisplatin alone or the ap-
plication of the electric pulses alone. When treatments were combined with tumor irradiation at either 3 or 5 Gy, the 
combination with electrochemotherapy was more effective: at 5 Gy, 2 animals out of 8 were in complete remission 
100 days later. In general the higher 5 Gy dose of γ-radiation was more effective than the lower one of 3 Gy. 
Conclusions. The results of our study demonstrate that irradiation doses, 3 Gy or 5 Gy, increase the antitumor ef-
fectiveness of electrochemotherapy with cisplatin on invasive ductal carcinoma tumors. Good antitumor results were 
achieved in experimental tumors with a size comparable to clinical lesions, demonstrating that this three-modality 
combined treatment is useful for the treatment of large lesions even at sub-optimal radiotherapy doses.
Key words: cisplatin; irradiation; electroporation; invasive ductal carcinoma; multimodalities 
Introduction 
Cisplatin is an anti-cancer chemotherapeutic drug 
that is administered to treat a large number of can-
cers such as those of the ovary, head and neck, cer-
vix and bladder, carcinomas as well as small-cell 
and non-small-cell lung cancers.1-5 However, resist-
ance to cisplatin is a clinical problem for the treat-
ment of some tumors.6 After an initial response 
to chemotherapy, tumors subsequently show the 
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minimal responsiveness to cisplatin.1,2,7 Besides 
direct cytotoxic effects, cisplatin has also the po-
tential to enhance radiation-induced cell killing.8-10 
Cisplatin as a radiosensitizer increases the damage 
to the nuclear DNA of malignant cells, enhancing 
the anti-neoplastic efficacy of the radiotherapy.9,10 
The combination of cisplatin and radiation is a 
common treatment modality with synergistic ef-
fects for cancers.4,5,8,9,11 Several in vitro and in vivo 
studies have shown higher response rates, pro-
longed mean survival, increased survival rates, 
longer local recurrence-free survival rates, and 
considerable organ preservation with the use of 
cisplatin in combination with external radiothera-
py.8-11 Indeed, it has been proven that cisplatin en-
hances the cytotoxicity of radiation on cells in vitro, 
on experimental tumors in vivo and in solid tumors 
in the clinic.12-14
Many studies have been performed to poten-
tiate cisplatin antitumor effectiveness. One way 
to increase the radiosensitizing effect of cispla-
tin can result from the increase of the cisplatin 
intracellular accumulation. Several studies have 
been conducted using different drug delivery 
systems to increase the amount of cisplatin in 
the tumor cells.8,14-18 Electropermeabilization is 
a physical method that uses short and intense 
electric pulses to facilitate drug delivery into the 
cells.19,20 Electrochemotherapy (ECT) combines 
the administration of specific chemotherapeutic 
drugs (bleomycin or cisplatin) with the applica-
tion of electric pulses to the tumors to locally in-
crease drug uptake and thus drug effectiveness.17,21 
Electrochemotherapy with bleomycin and cisplatin 
was elaborated in vitro, in vivo and in clinical tri-
als.15,16,21-25 Besides permeability, electroporation 
has other effects like a transient and reversible 
reduction of the blood flow.26 This reduction may 
contribute to the entrapment of the drug in the 
tumor, thereby providing more time for the drug 
to act. As this effect would reduce drug wash-out 
from the tumor, it could play a role in antitumor 
efficiency. 
It has been demonstrated that the electropora-
tion of tumors increases the radiosensitizing ef-
fect of cisplatin on small experimental tumors.27,28 
The enhanced radiosensitizing effect of cisplatin 
is actually due to the increased electroporation-
mediated cisplatin delivery into the tumor cells.29 
These initial studies used an already efficient dose 
of radiotherapy (RT) which was delivered to SA-
1 fibrosarcoma transplanted in mice, combined 
to electrochemotherapy using cisplatin as well as 
small tumors in mice.27 
The aim of the present study was to evaluate the 
efficiency of electrochemotherapy with cisplatin 
combined with a single radiotherapy dose on an 
animal model tumor of breast adenocarcinoma to 
determine the potentialities of this combination. 
Two sub-optimal radiotherapy conditions, 3 Gy or 
5 Gy, unable to generate long term partial respons-
es in this tumor model, were applied in these com-
binations. Moreover, it was decided to treat very 
large experimental tumors, of an average volume 
of 630 mm3, to assess the efficacy of the treatment 
alone or in combination in a preclinical model ex-
ploring the possibility of efficiently treating large 
lesions.  
Materials and methods 
Mice and tumors
Female Balb/C mice, purchased from the Pasteur 
Institute (Tehran, Iran) were maintained at 25˚C 
with natural day/night cycle for 10 days for ad-
aptation. Mice were 6–8 weeks old at the begin-
ning of the experiments. A fragment (4 mm3) of a 
spontaneous mouse mammary tumor (an invasive 
ductal carcinoma) was transplanted subcutane-
ously into the flank of each animal.30,31 Two weeks 
after the implantation, when the tumors reached 
approximately 630 mm3 in volume (12-15 mm in 
diameter), the mice were randomly divided into 
the experimental groups (8-10 animals for each 
control and each experimental group). The study 
was approved by the local Research and Medical 
Ethics Committee, in accordance with the Shahid 
Beheshti University of Medical Sciences Guidelines 
for the Care and Use of Laboratory Animals.
 
Cisplatin
Cisplatin (50 mg/ml, Ebewe Pharma, Austria) was 
diluted with 0.9% NaCl the day of the treatment. 
Cisplatin at a dose of 8 mg/kg was injected intra-
tumorally and the injected volume was adjusted to 
deliver 0.02 ml of this cisplatin solution per gram 
of body weight.
Electrochemotherapy  
Two flat stainless steel plates were mounted on a 
caliper to serve as 20 x 20 mm parallel electrodes. A 
distance between electrodes was adjusted by roll-
ing of the caliper depending on the tumor size. The 
voltage value was then set in an ECT-SBDC device 
(with a maximal output voltage of 1400 V) to gen-
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erate electric pulses with a voltage to distance ratio 
of 1000 V/cm. The electrodes and the ECT-SBDC 
device were designed in the electromagnetic labo-
ratory of the Medical Physics department of Tarbiat 
Modares University, Tehran, Iran. Eight square-
wave electric pulses (two trains of 4 pulses) of 1000 
V/cm amplitude, with a pulse duration of 100µs 
and repetition frequency 1 Hz, were delivered by 
the two parallel electrodes which were placed on 
the skin at the opposite sides of the tumor. An op-
timal contact between the electrodes and the skin 
was assured by means of a conductive gel. In all 
the electrochemotherapy groups, mice were treat-
ed with the electric pulses 1 min after the cisplatin 
injection.
Radiotherapy 
A cobalt-60 unit (Theraton 780, Canada) was 
used to locally deliver a single dose of 3 Gy or 5 
Gy at a dose rate of 0.6 Gy/min (3 Gy in 5 min) or 
0.71 Gy/min (5 Gy in 7 min). Irradiation was per-
formed frontally. As the smallest field covered by 
the Cobalt beam was 4 x 4 cm2, the mouse’s body 
around the tumor was shielded using lead blocks 
so as to leave only the tumor exposed to the irra-
diation beam. 
Study protocol
The experimental groups included: untreated tu-
mors as controls, tumors treated with cisplatin, 
electric pulses or radiotherapy alone, tumors treat-
ed by electrochemotherapy (that is cisplatin injec-
tion followed by the local application of electropo-
rative electric pulses) and tumors treated with the 
combination of cisplatin or electric pulses and ra-
diotherapy. In the combination of cisplatin or elec-
troporation with local radiotherapy, tumor-bear-
ing mice were irradiated 30 min after the cisplatin 
injection or the electric pulses delivery, to provide 
the time to cisplatin to enter the cells. 
Treatment evaluation 
Tumor growth was monitored, every three days, 
by measuring two mutually orthogonal tumor di-
ameters (e1 being the larger tumor diameter and 
e2 the largest diameter orthogonal to e1). Tumors 
were rather spherical and tumor volumes were cal-
culated by the formula V= π/6 × e1× e22. From the 
tumor growth curves, tumor-doubling time (DT) 
was determined for each individual tumor. Tumor 
growth delay (GD) was calculated by subtract-
ing the mean tumor volume doubling time of the 
untreated tumors (control) from the mean tumor 
volume doubling time of each experimental group. 
Inhibition ratio, expressed in percent, was calculat-
ed at day 30 after the treatment by the formula [1- 
(treated tumor average volume/untreated tumor 
average volume)] x100%. Partial response (PR) was 
a decrease by more than 50% of the tumor volume. 
Complete response (CR) was the absence of tumor 
for more than 100 days. 
TABLE 1. Tumor growth after treatment with three modalities; cisplatin, electric pulses and local γ-radiation or combination on invasive ductal carci-
noma tumor model
Experimental groups n DTdays, Mean±SE
GD
days, mean Inhibition ratio (%)
CR
number
Control 8 4.6±0.5 0 0
CDDP 8 10.6±1.21 5.5 33 0
EP 8 6.6±0.5 2.0 32 0
ECT 10 20.1±1.2 15.5 61 0
IR (3 Gy) 9 15.7±1.4 11.1 63 0
CDDP + IR (3 Gy) 9 15.9±2.4 11.3 61 0
EP + IR (3 Gy) 8 13.4±2.1 8.8 51 0
ECT + IR (3 Gy) 10 30.3±2.6 25.7 76 0
IR (5 Gy) 8 25.2±1.1 20.6 70 0
CDDP + IR (5 Gy) 8 25.6±1.2 21.0 75 0
EP + IR (5 Gy) 8 22.4±1.4 17.8 59 0
ECT + IR (5 Gy) 8 43.2±1.5 38.6 87 2
CDDP = cisplatin; EP = electric pulses; ECT = electrochemotherapy; IR = irradiation; n = number of mice in the experimental group; DT = tumor doubling time; GD = growth delay; 
PR = partial response; CR = complete response
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Normalized volumes at day N for each animal 
were calculated by dividing the tumor volume Vn 
at day N after the treatment by the average tumor 
volume V0 at day 0 that is at the day of the treat-
ment (Vn/V0). 
Statistical analysis
All data were tested for normality of distribution. 
The ANOVA test with repeated measures was used 
to evaluate statistical significance of differences be-
tween experimental and control groups at different 
times. A p-value<0.05 was considered significant in 
the statistical tests (*p <0.05).
 
Results
As shown in Table 1 and Figure 1, cisplatin (at a 
dose of 8 mg/kg) as a single treatment delayed the 
tumor growth up to 5.5 days with an inhibition ra-
tio of 33%. Tumors that were treated with electric 
pulses alone (8 pulses, 1000 V/cm, 100µs duration, 
at 1 Hz repetition frequency) displayed a tumor 
growth delay of only 2 days with an inhibition ra-
tio of 32% (Table 1) and with no partial or complete 
responders with neither of both treatment modali-
ties.  
In the electrochemotherapy group, in which tu-
mors were exposed to electric pulses 1 min after 
the cisplatin injection, a prolonged tumor growth 
delay (up to 15.5 days) was observed (p <0.05). The 
inhibition ratio reached 61% (Table 1). Thus, elec-
trochemotherapy was more effective than either 
cisplatin alone or the application of electric pulses 
alone, with moreover 30% partial response for the 
first 9 days (p <0.05). 
With local irradiation alone (Table 1 and Figures 
1 and 2), the higher dose (5 Gy) resulted in a growth 
delay up to 20.6 days. Tumors irradiated with a sin-
gle dose of 3 Gy resulted in a tumor growth delay 
of 11.1 days and an inhibition ratio of 63% (Table 1). 
Some partial responses (25%) were observed with-
in the 15 days that followed the administration of 5 
Gy, but only 11% with 3 Gy. 
When the administration of cisplatin was com-
bined with local irradiation performed 30 min after 
the drug injection, the treatment of tumors resulted 
in tumor growth delays and inhibition ratios of 11.3 
days and 61% respectively with a 3 Gy radiation 
and of 21.0 days and 75% with a 5 Gy irradiation 
(Table 1). These results demonstrate that a dose of 
5 Gy was more effective. This is also borne out by 
the fact that 25% partial responses were observed 
FIGURE 1. Tumor growth curves in untreated tumors or after treatment with CDDP 
(CDDP), electric pulses (EP) only, irradiation (IR) only, electrochemotherapy (ECT) and 
the combinations of CDDP or electric pulses and radiotherapy. Data are mean ± SE of 
at least 8 animals for each of the experimental groups. Irradiation of tumor was 3Gy.
FIGURE 3. Individual tumor growth curves of tumors treated by the combination of 
electrochemotherapy (ECT) and radiotherapy at the dose of 5 Gy. 
FIGURE 2. Tumor growth curves for invasive ductal carcinoma tumors after treatment 
with radiotherapy (IR) only, electrochemotherapy (ECT), combination of CDDP or 
electric pulses and radiotherapy at dose of 3 Gy in comparison to 5 Gy. Data are 
mean ± SE of at least 8 animals for each of the experimental groups.
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for up to 15 days with the 3 Gy irradiation, whereas 
only 11% partial responses were recorded up to 12 
days following the combination of cisplatin and 3 
Gy irradiation (p <0.05).
When electric pulses were combined with local 
irradiation delivered 30 min after the electric puls-
es application, an improved antitumor effect was 
not observed compared to irradiation alone. Tumor 
growth delays of 8.8 days and inhibition ratio of 
51% after 3 Gy and of 17.8 days and 59% after 5 
Gy were scored (Table 1). With 5 Gy, one partial 
response (12.5%) was achieved for 15 days with no 
partial responders after 3 Gy.  
Irradiation of tumors pretreated with electro-
chemotherapy prolonged the tumor growth delay 
up to 25.7 days and 38.6 days at 3 Gy and 5 Gy re-
spectively. The inhibition ratio reached 76% for the 
3 Gy irradiation and 87% for 5 Gy. Ten per cent of 
partial responses after 30 days were observed with 
electrochemotherapy followed by 3 Gy, though 
without complete responders. In contrast, the elec-
trochemotherapy with a 5 Gy irradiation resulted 
in a higher percentage of partial regressions (37% 
of the tumors were still in partial response 30 days 
after the treatment). Moreover, 25% of the mice 
were still in complete remission 100 days after the 
treatment (Table 1 and Figure 3). Again, the combi-
nation with 5 Gy was significantly (p <0.05) more 
efficient than the combination with 3 Gy. Even in 
this group, no body weight loss or skin desquama-
tion was reported. Only a hair loss was observed 
in all the groups that were irradiated, locally at the 
level of the irradiation site.
In summary, in all the cases, the combination 
with γ- radiation resulted in a larger antitumor ef-
ficacy than without the combination with γ-rays. 
Discussion
In this study, the therapeutic effects of cisplatin, 
electroporation, γ-radiation and combination of 
these treatments were evaluated in a murine in-
vasive ductal carcinoma tumor model. Our data 
confirm and extend previous findings16-18 showing 
that the delivery to tumors of electric pulses and 
cisplatin enhances the cisplatin-induced radiosen-
sitization. 
Electroporation combined with cisplatin has 
shown a significant effectiveness both in vitro and 
in vivo, as well as in clinical studies in the treatment 
of patients with cutaneous tumor nodules.15-18,24,25 
Although the increased radiosensitizing effect of 
cisplatin using electroporation has been shown in 
EAT carcinoma and LPB sarcoma cells27,28, data on 
radiosensitization for large tumors, of a size closer 
to clinical situations, have not yet been reported. In 
this study, this issue was addressed and using lo-
cal γ-radiation with single doses of 3 Gy or 5 Gy of 
Cobalt-60 γ-rays in combination with electroche-
motherapy with cisplatin on large invasive ductal 
carcinoma tumors as a model for the treatment of 
large breast tumors. 
Our study confirms that electrochemotherapy 
was more effective than individual treatments us-
ing cisplatin or electric pulses alone which is con-
sistent with previous reports.16-18,27,28 When electro-
chemotherapy with cisplatin was combined with 
local irradiation, the antitumor efficiency was dou-
bled. This three-modality therapy was better than 
electrochemotherapy, cisplatin combined with lo-
cal tumor irradiation and electric pulses combined 
with irradiation. In addition, some tumors were 
still in complete remission 100 days after the treat-
ment at single dose of 5 Gy. It is important to high-
light that the irradiation doses used in the present 
study (a single 3 Gy or 5 Gy dose) are lower than 
the doses used in the previous experimental stud-
ies with cisplatin reported here above.27,28 Indeed, 
Sersa et al. used a dose of 15 Gy for electrochemo-
therapy with cisplatin combined with irradiation 
on the EAT tumor animal model.27 However, there 
are studies that demonstrated an increase of the tu-
mor curability dose (TCD50) for both cisplatin (be-
ing 1.6) and bleomycin (1.9).32,33
This study concentrated on electrochemother-
apy with cisplatin, as cisplatin is a radiosentizer, 
with the aim also to show that electrochemothera-
py can radiosensitize the tumors. However, the ini-
tial goal was to determine whether electrochemo-
therapy efficacy could be increased by irradiation 
even in large tumors. Indeed, using about the same 
dose rate 2.2 Gy/min (10-20 Gy), Sersa et al. showed 
that efficacy of electrochemotherapy with bleomy-
cin (a molecule considered a radiomimetic but not 
a radiosensitizer) was increased with irradiation, 
on SA-1 and CaNT tumor models.32 
 Finally it is important to report that our 
results are also in agreement with two clinical 
studies34,35 reporting that electrochemotherapy in 
combination with irradiation is an effective and 
safe treatment for tumors of various origins in pa-
tients, thus on lesions of a size at least comparable 
to those treated in this study.
In conclusion the results of this study demon-
strate that electrochemotherapy with cisplatin ra-
diosensitized the tumors to a single low irradiation 
dose (3 Gy or 5 Gy of Cobalt-60 γ-rays) on invasive 
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ductal carcinoma tumors. Moreover, this three-mo-
dality combined treatment was useful for the treat-
ment of large lesions even at sub-optimal doses of 
irradiation. Complete response of very large tu-
mors could be achieved after a single session with 
the combined multimodality treatment. 
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